Case Reports

. 2018 Aug;150(2):219-226.

doi: 10.1016/j.ygyno.2018.05.028. Epub 2018 Jun 22.

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor

Allison A Gockley¹, David L Kolin², Christopher S Awtrey³, Neal I Lindeman⁴, Ursula A Matulonis⁵, Panagiotis A Konstantinopoulos⁶

Affiliations

¹ Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
³ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Beth-Israel Deaconess Medical Center, Boston, MA 02130, USA.
⁴ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁶ Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Panagiotis_konstantinopouos@dfci.harvard.edu.

PMID: 29937315
DOI: 10.1016/j.ygyno.2018.05.028

Case Reports

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor

Allison A Gockley et al. Gynecol Oncol. 2018 Aug.

. 2018 Aug;150(2):219-226.

doi: 10.1016/j.ygyno.2018.05.028. Epub 2018 Jun 22.

Authors

Allison A Gockley¹, David L Kolin², Christopher S Awtrey³, Neal I Lindeman⁴, Ursula A Matulonis⁵, Panagiotis A Konstantinopoulos⁶

Affiliations

¹ Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
³ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Beth-Israel Deaconess Medical Center, Boston, MA 02130, USA.
⁴ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁶ Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Panagiotis_konstantinopouos@dfci.harvard.edu.

PMID: 29937315
DOI: 10.1016/j.ygyno.2018.05.028

Abstract

A 42-year-old woman with a germline BRCA2 mutation and recurrent low-grade endometrioid endometrial adenocarcinoma experienced clinical and radiographic response to the poly (ADP ribose) polymerase (PARP) inhibitor, olaparib. Molecular and treatment factors are discussed.

PubMed Disclaimer

Cited by

Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report.
Inoue K, Tsubamoto H, Ueda T, Tajima C, Nakagomi N. Inoue K, et al. Gynecol Oncol Rep. 2020 Apr 5;32:100563. doi: 10.1016/j.gore.2020.100563. eCollection 2020 May. Gynecol Oncol Rep. 2020. PMID: 32300630 Free PMC article.
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives.
Musacchio L, Caruso G, Pisano C, Cecere SC, Di Napoli M, Attademo L, Tambaro R, Russo D, Califano D, Palaia I, Muzii L, Benedetti Panici P, Pignata S. Musacchio L, et al. Cancer Manag Res. 2020 Jul 22;12:6123-6135. doi: 10.2147/CMAR.S221001. eCollection 2020. Cancer Manag Res. 2020. PMID: 32801862 Free PMC article. Review.
Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G, Vandenberg CJ, Nesic K, Ratnayake G, Zhu W, Vissers JHA, Bedő J, Penington J, Wakefield MJ, Kee D, Carmagnac A, Lim R, Shield-Artin K, Milesi B, Lobley A, Kyran EL, O'Grady E, Tram J, Zhou W, Nugawela D, Stewart KP, Caldwell R, Papadopoulos L, Ng AP, Dobrovic A, Fox SB, McNally O, Power JD, Meniawy T, Tan TH, Collins IM, Klein O, Barnett S, Olesen I, Hamilton A, Hofmann O, Grimmond S, Papenfuss AT, Scott CL, Barker HE. Dall G, et al. J Exp Clin Cancer Res. 2023 May 4;42(1):112. doi: 10.1186/s13046-023-02687-0. J Exp Clin Cancer Res. 2023. PMID: 37143137 Free PMC article.
Targeting DNA Damage Repair and Immune Checkpoint Proteins for Optimizing the Treatment of Endometrial Cancer.
Bian X, Sun C, Cheng J, Hong B. Bian X, et al. Pharmaceutics. 2023 Aug 30;15(9):2241. doi: 10.3390/pharmaceutics15092241. Pharmaceutics. 2023. PMID: 37765210 Free PMC article. Review.
Poly (ADP-ribose) polymerase inhibitors in cancer therapy.
Zhu Z, Shi Y. Zhu Z, et al. Chin Med J (Engl). 2025 Mar 20;138(6):634-650. doi: 10.1097/CM9.0000000000003471. Epub 2025 Feb 11. Chin Med J (Engl). 2025. PMID: 39932206 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- ClinicalTrials.gov
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor

Affiliations

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous